NCT05849480 2026-02-05A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)National Institutes of Health Clinical Center (CC)Phase 1/2 Recruiting60 enrolled
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT04003636 2025-04-23KEYNOTE-966Merck Sharp & Dohme LLCPhase 3 Completed1,069 enrolled 19 charts 1 FDA